Bullfrog AI Holdings, Inc. Common Stock logo

Bullfrog AI Holdings, Inc. Common Stock(BFRG)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.54
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BFRG

11/13/2026: BFRG (1-star) is currently NOT-A-BUY. Pass it for now.

Bullfrog AI Holdings is a micro-cap digital biopharmaceutical company that leverages proprietary artificial intelligence platforms, such as bfLEAP and bfARENAS, to optimize drug discovery and clinical trial stratification. The company's primary growth opportunity centers on expanding high-value biopharma collaborations and advancing internal therapeutic pipelines for oncology and CNS disorders. However, it faces substantial risks, including early-stage revenue generation, ongoing operational cash burn, and intense competition within the life sciences analytics sector. The stock suits high-risk growth investors comfortable with micro-cap volatility, while key developments to monitor include pharma partnership updates and clinical pipeline milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers exposure to high-growth AI biotech themes, but lacks scaled commercial revenues at this early stage.
Momentum investorStrong fit while signal remains positiveMicro-cap float and clinical updates can trigger sharp momentum rallies when market sentiment is favorable.
Value investorWeak fitThe lack of consistent earnings and current net losses makes traditional valuation metrics unsupportive.
Dividend investorWeak fitThe company pays no dividends as it prioritizes clinical pipeline and technology scaling.
Low-risk investorWeak fitHigh price volatility, regulatory risks, and micro-cap liquidity create substantial risk exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap status and low daily trading volumes lead to sharp equity swings.
Valuation riskMedium / highValuation relies heavily on speculative future pipeline potential rather than current cash flows.
Competition risk (AI competition)HighThe company competes with numerous well-funded machine learning and bioinformatics firms.
Business qualityMediumWhile technology platforms like bfLEAP show promise, commercial validation is still unfolding.
Dividend incomeLow / noneNo dividend is paid to investors.
Execution riskHighSuccess depends entirely on complex clinical trial outcomes and pharma partnership conversion.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.04M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 2.3M shares
Beta -2.62
52 Weeks Range 0.43 - 1.96
Updated Date 11/15/2026
52 Weeks Range 0.43 - 1.96
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.46

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Health Information Services

BUY participation
100.0%
Active BUY / eligible
4 / 4
30-Day BUY Count Change
+2

Eligible universe: 4 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -55.51%
Avg. Invested days 8
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BFRG receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by soft unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
BFRG has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+7.1%) is partially offset by weak cash generation (FCF margin -4733.2%), slightly negative revenue growth (+0.0%), weak profitability (net margin -5569.6%).

Financial Health Rating

★★★★★
BFRG's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 68.1%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is BFRG's strongest growth driver at +7.1% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 6.4% and approximately 86.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 13.54% supports management-shareholder alignment.

Top 5 Institutional Investors

Citadel Advisors Llc 1.95%
J. Safra Sarasin Holding AG 0.61%
Vanguard Fiduciary Trust Co 0.57%
Geode Capital Management, LLC 0.57%
Vanguard Capital Management, LLC 0.49%

Unit Economics (Per $1K Revenue)

★★★★★
BFRG generates approximately $188 of gross profit, $-56,524 of operating income, and $-47,332 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
BFRG has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
AI Analytics & Platform ServicesFees and partnership arrangements for deploying bfLEAP and bfARENAS platforms to evaluate third-party preclinical and clinical datasets.The company earns revenue by helping other drug developers analyze complex medical data using its proprietary software.
Biopharmaceutical Licensing & Co-DevelopmentUpfront payments, milestone markers, and potential royalties derived from internal drug assets and joint ventures.Long-term upside depends on successfully licensing out or co-developing novel therapeutic compounds.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3.21M
Price to Sales(TTM) 33.6
Enterprise Value 3.21M
Price to Sales(TTM) 33.6
Enterprise Value to Revenue 10.75
Enterprise Value to EBITDA -12.02
Shares Outstanding 18.54M
Shares Floating 15.97M
Shares Outstanding 18.54M
Shares Floating 15.97M
Percent Insiders 13.54
Percent Institutions 6.38

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.